JP2013163690A - Composition containing coenzyme q10 - Google Patents
Composition containing coenzyme q10 Download PDFInfo
- Publication number
- JP2013163690A JP2013163690A JP2013105394A JP2013105394A JP2013163690A JP 2013163690 A JP2013163690 A JP 2013163690A JP 2013105394 A JP2013105394 A JP 2013105394A JP 2013105394 A JP2013105394 A JP 2013105394A JP 2013163690 A JP2013163690 A JP 2013163690A
- Authority
- JP
- Japan
- Prior art keywords
- coenzyme
- sesamin
- composition
- oil
- action
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title claims abstract description 124
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 123
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 120
- 229940110767 coenzyme Q10 Drugs 0.000 claims abstract description 110
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 claims abstract description 103
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 claims abstract description 99
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 claims abstract description 92
- 238000001727 in vivo Methods 0.000 claims abstract description 18
- 238000002156 mixing Methods 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 11
- 239000012141 concentrate Substances 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 230000009471 action Effects 0.000 description 17
- 239000008159 sesame oil Substances 0.000 description 14
- 235000011803 sesame oil Nutrition 0.000 description 14
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 238000013329 compounding Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000004006 olive oil Substances 0.000 description 5
- 235000008390 olive oil Nutrition 0.000 description 5
- 239000012264 purified product Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 229930003427 Vitamin E Natural products 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 230000009965 odorless effect Effects 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 230000009967 tasteless effect Effects 0.000 description 3
- SOECUQMRSRVZQQ-UHFFFAOYSA-N ubiquinone-1 Chemical compound COC1=C(OC)C(=O)C(CC=C(C)C)=C(C)C1=O SOECUQMRSRVZQQ-UHFFFAOYSA-N 0.000 description 3
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000013736 caramel Nutrition 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ARZCDYVIZADZJN-QXCSMICNSA-N (2r)-7,8-dimethoxy-2,5-dimethyl-2-[(3e,7e,11e,15e,19e,23e,27e,31e)-4,8,12,16,20,24,28,32,36-nonamethylheptatriaconta-3,7,11,15,19,23,27,31,35-nonaenyl]chromen-6-ol Chemical compound C1=C[C@@](C)(CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)OC2=C(OC)C(OC)=C(O)C(C)=C21 ARZCDYVIZADZJN-QXCSMICNSA-N 0.000 description 1
- 102100034542 Acyl-CoA (8-3)-desaturase Human genes 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 102100022043 Coenzyme Q-binding protein COQ10 homolog A, mitochondrial Human genes 0.000 description 1
- 101710154595 Coenzyme Q-binding protein COQ10 homolog A, mitochondrial Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010073542 Delta-5 Fatty Acid Desaturase Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- ARZCDYVIZADZJN-OBEXFZABSA-N Ubichromenol Natural products COc1c(O)c(C)c2C=C[C@@](C)(CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)Oc2c1OC ARZCDYVIZADZJN-OBEXFZABSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000014106 fortified food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- -1 glycerin fatty acid ester Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical class CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001782 photodegradation Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- KQRXQIPRDKVZPW-ISZNXKAUSA-N sesaminol Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=3OCOC=3C=C2O)=C1 KQRXQIPRDKVZPW-ISZNXKAUSA-N 0.000 description 1
- KQRXQIPRDKVZPW-UHFFFAOYSA-N sesaminol Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=3OCOC=3C=C2O)=C1 KQRXQIPRDKVZPW-UHFFFAOYSA-N 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000010698 whale oil Substances 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、コエンザイムQ10を含有した組成物に関し、更に詳細にはセサミン類を配
合したコエンザイムQ10の高吸収性組成物及びこれを含有した飲食品に関する。
The present invention relates to a composition containing coenzyme Q10, and more particularly to a superabsorbent composition of coenzyme Q10 containing sesamin and a food and drink containing the same.
コエンザイムQ10は、別名、補酵素Q10、ビタミンQ、ユビキノン及びユビデカレ
ノン(分子式:C59H90O4、分子量:863.36)として知られ、その融点は約
48℃であり、水に殆ど溶けない物質であるが、エーテルなどには高い溶解性を示し、光
により分解してヒドロキノン体やユビクロメノールなどを生成する物質として知られてい
る。
Coenzyme Q10, also known as coenzyme Q10, vitamin Q, ubiquinone and ubidecalenone (molecular formula: C 59 H 90 O 4 , molecular weight: 863.36), has a melting point of about 48 ° C. and is hardly soluble in water. Although it is a substance, it is known as a substance that exhibits high solubility in ether and decomposes by light to produce hydroquinone, ubichromenol, and the like.
このコエンザイムQ10は、動物細胞のミトコンドリアがエネルギーを産生する際の補
酵素として必須の物質であり、また酸素利用効率を改善する作用を有するビタミン様作用
物質として知られている。
This coenzyme Q10 is an essential substance as a coenzyme when the mitochondria of animal cells produce energy, and is known as a vitamin-like substance having an action of improving oxygen utilization efficiency.
コエンザイムQ10の主な薬理作用としては、抗酸化作用、エネルギー産生促進作用、
心肺機能を高める作用、免疫賦活作用、老化予防作用などがあり、食品への添加物として
または栄養補助食品中の成分などとしても利用されている。
The main pharmacological actions of coenzyme Q10 include antioxidant action, energy production promoting action,
It has an action to enhance cardiopulmonary function, an immunostimulatory action, an aging preventive action, etc., and is also used as an additive to foods or as a component in dietary supplements.
また、食品中では肉類や卵にも数μg/g程度含まれ、生体内でも合成される栄養素で
あるが、加齢により生体内での合成量も減少し、欠乏しがちになる。しかしながら、コエ
ンザイムQ10含量の高い天然食品素材はごく少ないことから、通常の食事だけでは、不
足を補う量のコエンザイムQ10を摂取することは難しい。また高齢者に多い心疾患、例
えば、虚血性心疾患等の予防または症状の軽減などのためにも、コエンザイムQ10を栄
養補助薬品や栄養強化食品などから補給することが望ましい。
In addition, in foods, meat and eggs are contained in the order of several μg / g, and are also synthesized in vivo. However, the amount of synthesis in vivo decreases with age and tends to be deficient. However, since there are very few natural food materials with a high coenzyme Q10 content, it is difficult to ingest an amount of coenzyme Q10 that compensates for the deficiency with only a normal meal. In addition, it is desirable to supplement coenzyme Q10 from nutritional supplements or fortified foods in order to prevent heart disease such as ischemic heart disease that is common in elderly people or to reduce symptoms.
さらに、このコエンザイムQ10は融点の低い親油性固体であり、水に難溶性であり、
油脂などの基剤への溶解度が極めて低いため、経口投与における吸収性が低いことが知ら
れている。コエンザイムQ10の吸収性の向上を図り、且つ結晶化、凝集沈殿などを起こ
さないようにすることが求められる。また、経口的に摂取することから、コエンザイムQ
10含有組成物の安全性が高いことも重要であることを考慮しつつ、吸収性を改善するた
めに、さまざまな検討がなされている。例えば、コエンザイムQ10を油に加熱溶解する
こと(特許文献1)、水溶化するための技術を使用すること(特許文献2)、及びシクロ
デキストリンで包接化する技術を用いること(特許文献3)が提案されている。
It is known that the solubility in oral administration is low because of its extremely low solubility in bases such as fats and oils. It is required to improve the absorbability of coenzyme Q10 and prevent crystallization, aggregation precipitation and the like. In addition, since it is taken orally, coenzyme Q
Considering that the safety of the 10-containing composition is also important, various studies have been made to improve the absorbability. For example, heat-dissolving coenzyme Q10 in oil (Patent Document 1), using a technique for water-solubilization (Patent Document 2), and using a technique of inclusion with cyclodextrin (Patent Document 3) Has been proposed.
上記のとおり、種々のコエンザイムQ10含有素材が知られているものの、体内吸収性
および生産性の観点から満足できるものは存在していなかった。例えば、特許文献1に記
載のコエンザイムQ10を油に加熱溶解することで得られたコエンザイムQ10含有素材
では、経口投与における体内吸収が十分でないという問題がある。特許文献2に記載のコ
エンザイムQ10を水溶化する技術では、カゼインNa、デキストリン及びコエンザイム
Q10を混合・攪拌後、凍結乾燥するという工程を経なければならない。また、特許文献
3に記載の、コエンザイムQ10をシクロデキストリンで包接する技術では、包接化する
ための煩雑な工程を経なければならない。このように、特許文献2に記載の水溶化技術や
特許文献3に記載のシクロデキストリン包接技術は製造工程が複雑であり、これらの技術
によって得られるコエンザイムQ10含有素材の生産コストが高価になるという問題があ
った。
As described above, although various coenzyme Q10-containing materials are known, there are no materials that can be satisfied from the viewpoint of in vivo absorbability and productivity. For example, the coenzyme Q10-containing material obtained by heating and dissolving Coenzyme Q10 described in Patent Document 1 in oil has a problem that absorption in the body by oral administration is not sufficient. In the technology for water-solubilizing coenzyme Q10 described in
したがって、本発明の課題は、工業的に製造が容易で、かつ生産コストも低い製法によ
り、体内吸収性が改善されたコエンザイムQ10含有組成物を提供することである。
Therefore, an object of the present invention is to provide a coenzyme Q10-containing composition having improved in-vivo absorbability by a production method that is industrially easy to produce and low in production cost.
本発明者は、上記の課題解決のために鋭意研究の結果、コエンザイムQ10にセサミン
類を含有させることにより、コエンザイムQ10の体内吸収性が著しく改善されることを
見出し、本発明を完成させたのである。
As a result of diligent research to solve the above problems, the present inventor found that the in vivo absorbability of coenzyme Q10 was significantly improved by incorporating coenzyme Q10 with sesamin, and thus completed the present invention. is there.
すなわち、本発明は次のような構成をとるものである。
1. セサミン類と、コエンザイムQ10とを含む組成物。
2. セサミン類のコエンザイムQ10に対する配合重量比が、1/10以上である上記
1に記載の組成物。
3. 前記配合重量比が、1/3〜1/1である上記2に記載の組成物。
4. セサミン類が、セサミン類を1%以上含有するセサミン類濃縮物である上記1〜3
のいずれかに記載の組成物。
5. 前記セサミン類濃縮物が、セサミン類を20%以上含有する、上記4に記載の組成
物。
6. セサミン類が、セサミン及び/又はエピセサミンである上記1〜5のいずれかに記
載の組成物。
7. 上記1〜6のいずれかに記載の組成物を含有した飲食物。
8. コエンザイムQ10にセサミン類を配合することを特徴とする、コエンザイムQ1
0の体内吸収性を高める方法。
That is, the present invention has the following configuration.
1. A composition comprising sesamin and coenzyme Q10.
2. 2. The composition according to 1 above, wherein the blending weight ratio of sesamin to coenzyme Q10 is 1/10 or more.
3. 3. The composition according to 2 above, wherein the blending weight ratio is 1/3 to 1/1.
4). The above 1 to 3, wherein the sesamin is a sesamin concentrate containing 1% or more of the sesamin
The composition in any one of.
5. 5. The composition according to 4 above, wherein the sesamin concentrate contains 20% or more of sesamin.
6). 6. The composition according to any one of 1 to 5 above, wherein the sesamin is sesamin and / or episesamin.
7). Food / drink containing the composition in any one of said 1-6.
8). Coenzyme Q1 characterized in that it contains sesamin in coenzyme Q10
A method to increase the absorption of zero in the body.
(セサミン類)
本発明は、コエンザイムQ10にセサミン類を配合することにより、コエンザイムQ1
0の体内吸収性を向上させるものである。本発明に用いることができるセサミン類として
は、セサミン及びその類縁体を含むものであり、セサミン類縁体としては、エピセサミン
の他、例えば特開平4−9331号公報に記載されたジオキサビシクロ〔3.3.0〕オ
クタン誘導体がある。セサミン類の具体例としては、セサミン、セサミノール、エピセサ
ミノール、セサモリン等を例示できる。なかでも、セサミン及びエピセサミンは、これら
が持つ種々の生理作用をコエンザイムQ10の作用と相加的に、または相乗的に発揮しう
ると考えられることから、より好ましい態様として例示できる。ここで、セサミン及びエ
ピセサミンの持つ生理作用としては、Δ5不飽和化酵素阻害作用(およびその作用に起因
する抗炎症作用、抗血栓作用、血圧降下作用等:S. Shimizu et al., J. Am. Oil Chem.
Soc., 66, 237-241 (1989); S. Shimizu et al., Lipid, 26, 512 (1991) ;特開平3−
27319)、脂質に対する抗酸化作用(特開平5−051388および特開2001−
139579)、抗高血圧作用(特開平8−268887)、肝機能改善作用(特開平4
−099331)、活性酸素消去作用(特開平6−227977)、血中コレステロール
低下作用及び/又はコレステロール低下作用(特許第3001589号および特開平4−
159221)、高度不飽和脂肪酸の生体内安定化作用(特開平11−269456)、
悪酔防止作用(特許第3124062号)などが挙げられる。
(Sesamin)
The present invention provides coenzyme Q1 by adding sesamin to coenzyme Q10.
It improves the absorbability of 0 in the body. Examples of sesamin that can be used in the present invention include sesamin and its analogs. Examples of sesamin analogs include episesamin and dioxabicyclo [3] described in JP-A-4-9331. .3.0] octane derivatives. Specific examples of sesamin can include sesamin, sesaminol, episesaminol, sesamorin and the like. Among these, sesamin and episesamin can be exemplified as a more preferred embodiment because they are thought to be able to exert various physiological actions of these in addition to or synergistically with the action of coenzyme Q10. Here, as physiological functions of sesamin and episesamin, Δ5 desaturase inhibitory action (and anti-inflammatory action, antithrombotic action, blood pressure lowering action, etc. resulting from the action: S. Shimizu et al., J. Am Oil Chem.
Soc., 66, 237-241 (1989); S. Shimizu et al., Lipid, 26, 512 (1991);
27319), antioxidant activity on lipids (JP-A-5-05388 and JP-A-2001-2001)
139579), antihypertensive action (JP-A-8-268887), liver function-improving action (JP-A-4-4
-099331), active oxygen scavenging action (Japanese Patent Laid-Open No. 6-227777), blood cholesterol lowering action and / or cholesterol lowering action (Japanese Patent No. 3001589 and Japanese Patent Laid-Open No. Hei 4-
159221), in vivo stabilization action of polyunsaturated fatty acids (JP-A-11-269456),
Examples include an anti-drunk action (Japanese Patent No. 3124062).
なお、セサミン類の代謝体も、本発明の効果を示す限り、本発明のセサミン類に含まれ
るセサミン類縁体であり、本発明に使用することができる。
本発明に用いるセサミン類は、その形態や製造方法等によって、何ら制限されるもので
はない。例えば、セサミン類としてセサミンを選択した場合には、通常、ごま油から公知
の方法(例えば、特開平4−9331号公報に記載された方法)によって抽出したセサミ
ン(セサミン抽出物または精製物という)を用いることもできるが、市販のごま油(液状
)をそのまま用いることもできる。しかしながら、ごま油を用いた場合には、ごま油特有
の風味が官能的に好ましくないと評価されることもあることから、無味無臭であるごま油
から抽出されたセサミン抽出物(又はセサミン精製物)を用いることが好ましい。また、
ごま油を用いた場合、セサミン含有量が低いため、好ましい量のセサミンを配合しようと
すると、選られるコエンザイムQ10含有組成物の体積が大きくなり過ぎるため、摂取に
不都合を生じることがある。特に、経口投与用に製剤化した場合は、製剤(錠剤、カプセ
ルなど)が大きくなり摂取に支障が生じる。したがって、摂取量が少くてよいという観点
からもごま油からのセサミン抽出物(又はセサミン精製物)を用いることが好ましい。
(コエンザイムQ10含有組成物)
本発明に係る組成物におけるセサミン類の配合量は、セサミン類のコエンザイムQ10
に対する配合重量比率が、1/10以上であることが好ましい。上記の比率で配合すると
、コエンザイムQ10の体内吸収性を向上させることができるが(実施例3)、セサミン
類のコエンザイムQ10に対する配合重量比率が1/15以下であると、コエンザイムQ
10の体内吸収性をごくわずかしか向上させることができない(実施例4)。
In addition, as long as the metabolite of sesamin shows the effect of this invention, it is a sesamin analog contained in the sesamin of this invention, and can be used for this invention.
The sesamin used for this invention is not restrict | limited at all by the form, manufacturing method, etc. For example, when sesamin is selected as the sesamin, usually sesamin extracted from sesame oil by a known method (for example, the method described in JP-A-4-9331) (referred to as sesamin extract or purified product) Although it can also be used, commercially available sesame oil (liquid form) can also be used as it is. However, when sesame oil is used, the flavor unique to sesame oil may be evaluated to be sensory unfavorable, so a sesamin extract extracted from tasteless odorless sesame oil (or a sesamin purified product) is used. It is preferable. Also,
When sesame oil is used, since the sesamin content is low, when trying to add a preferable amount of sesamin, the volume of the selected coenzyme Q10-containing composition becomes too large, which may cause inconvenience in consumption. In particular, when it is formulated for oral administration, the formulation (tablets, capsules, etc.) becomes large and obstructs intake. Therefore, it is preferable to use a sesamin extract (or a sesamin purified product) from sesame oil from the viewpoint that the intake may be small.
(Coenzyme Q10-containing composition)
The blending amount of sesamin in the composition according to the present invention is the coenzyme Q10 of sesamin.
It is preferable that the mixing | blending weight ratio with respect to is 1/10 or more. When blended in the above ratio, the in vivo absorbability of coenzyme Q10 can be improved (Example 3), but if the blended weight ratio of sesamin to coenzyme Q10 is 1/15 or less, coenzyme Q
The in vivo absorbability of 10 can be improved only slightly (Example 4).
本発明のセサミン類とコエンザイムQ10とを含む組成物は、上述したとおり、コエン
ザイムQ10の体内吸収性を向上させるばかりでなく、セサミン類の持つ種々の生理作用
をコエンザイムQ10の作用と相加的に、または相乗的に発揮しうると考えられることか
ら、セサミン類の生理作用を発揮させることを考慮するならば、配合比率の上限はない。
しかし、コエンザイムQ10の体内吸収性の向上を目的としてセサミン類を配合するので
あれば、セサミン類のコエンザイムQ10に対する配合量比率が1/3〜1/1で、コエ
ンザイムQ10の体内吸収性はほぼ一定となると考えられることから(実施例1〜4、図
5)、セサミン類のコエンザイムQ10に対する配合量比率は、1/10以上であること
が好ましく、1/3〜1/1であることが更に好ましい。なお、セサミン類をコエンザイ
ムQ10に対し配合量比率で1/3配合した組成物を摂取したヒトにおいて、コエンザイ
ムQ10の体内吸収性を調べたところ、セサミン類を同時に摂取していないヒトよりもコ
エンザイムQ10の血中濃度が高くなる、すなわち体内吸収性が向上していることが確認
されている(実施例7)。
As described above, the composition containing the sesamin of the present invention and coenzyme Q10 not only improves the in vivo absorbability of coenzyme Q10, but also adds various physiological actions of sesamin to the action of coenzyme Q10. If it is considered that the physiological action of sesamin is exerted, there is no upper limit of the blending ratio.
However, if sesamin is added for the purpose of improving the in vivo absorbability of coenzyme Q10, the ratio of sesamin to coenzyme Q10 is 1/3 to 1/1, and the in vivo absorbability of coenzyme Q10 is almost constant. (Examples 1-4, FIG. 5), the blending ratio of sesamin to coenzyme Q10 is preferably 1/10 or more, and more preferably 1/3 to 1/1. preferable. In humans who ingested a composition containing 1/3 of sesamin to coenzyme Q10 at a compounding ratio, the in vivo absorbability of coenzyme Q10 was examined. Coenzyme Q10 was better than that of humans who were not ingesting sesamin simultaneously. It has been confirmed that the blood concentration of is increased, that is, the absorbability in the body is improved (Example 7).
本発明においては、その効果を損なわない限り、上記セサミン類とコエンザイムQ10
の他に、任意の所望成分を配合することができる。例えば、ビタミンE、ビタミンC等の
ビタミン類やソフトカプセルを調製する時に通常配合される乳化剤、緊張化剤(等張化剤
)、緩衝剤、溶解補助剤、防腐剤、安定化剤、抗酸化剤等を適宜配合することができる。
In the present invention, unless the effect is impaired, the sesamin and coenzyme Q10
In addition, arbitrary desired components can be blended. For example, vitamins such as vitamin E and vitamin C, and emulsifiers, tonicity agents (isotonic agents), buffers, solubilizers, preservatives, stabilizers, antioxidants, etc. that are usually blended when preparing soft capsules Etc. can be suitably blended.
本発明で使用するコエンザイムQ10の日用量は、摂取者の健康状態等により異なるが
、通常は1〜300mgの範囲、好ましくは10〜100mgである。また、セサミン類
の日用量は、通常は1〜60mg、好ましくは5〜60mgである。
The daily dose of coenzyme Q10 used in the present invention varies depending on the health condition of the intake person, but is usually in the range of 1 to 300 mg, preferably 10 to 100 mg. The daily dose of sesamin is usually 1 to 60 mg, preferably 5 to 60 mg.
本発明のコエンザイムQ10とセサミン類とを含有する組成物では、通常、コエンザイ
ムQ10を上記の日用量で使用し、セサミン類をその1/10〜1/1の重量比で配合す
るすることができる。
In the composition containing coenzyme Q10 and sesamin of the present invention, coenzyme Q10 is usually used at the above-mentioned daily dose, and sesamin can be blended at a weight ratio of 1/10 to 1/1. .
本発明のコエンザイムQ10とセサミン類とを含有する組成物は、コエンザイムQ10
の体内吸収性に優れているので、コエンザイムQ10の生理作用(例えば、抗酸化作用、
エネルギー産生促進作用、心肺機能を高める作用、免疫賦活作用、老化予防作用)が効率
よく発揮され、これらの生理作用を備えた健康食品として利用できる。ここでいう健康食
品とは、例えばカプセル剤や錠剤のように、本発明のコエンザイムQ10とセサミン類と
を含有する組成物そのものを有効成分とする製剤又は食品、ならびに一般の食品に上記本
発明組成物を1つの成分として配合して、その食品に生体に対する抗酸化機能等の種々の
機能を付加してなる機能性食品(特定保健用食品や条件付き特定保健用食品が含まれる)
を挙げることができる。さらに、生体における酸化反応またはそれによって生じる障害を
予防ないし抑制するために用いられる旨の表示を付してなる、生体抗酸化作用を有するこ
とを特徴とする食品等も包含されるものとする。
A composition containing coenzyme Q10 of the present invention and sesamin is a coenzyme Q10.
Because of its excellent absorbability in the body, the physiological action of coenzyme Q10 (for example, antioxidant action,
Energy production promoting action, cardiopulmonary function enhancing action, immunostimulating action, and aging preventing action) are efficiently exhibited and can be used as a health food with these physiological actions. The health food here is, for example, a preparation or food containing the composition itself containing the coenzyme Q10 of the present invention and sesamin as an active ingredient, such as capsules and tablets, and the composition of the present invention in general foods. Functional foods that contain products as a component and add various functions such as antioxidants to living bodies (including foods for specified health use and conditionally specified health foods)
Can be mentioned. Furthermore, foods and the like characterized by having a biological antioxidant effect, which are used to prevent or suppress an oxidation reaction in the living body or a disorder caused thereby, are also included.
コエンザイムQ10とセサミン類とを含有する健康食品としては、その形態を特に制限
するものではなく、例えば、粉末状、顆粒状、錠剤状などの固体状;液状、乳液状等の溶
液状;またはペースト状等の半固体状などの、任意の形態に調製することができる。具体
的な製剤を例示すれば、コエンザイムQ10と、セサミン及び/又はエピセサミンとを含
有する組成物を有効成分とする食品の場合には、それらの成分のいずれもが脂溶性である
ため、マイクロカプセル、ソフトカプセル又はハードカプセルに封入してカプセル化する
ことにより、栄養補給、または補助的に栄養成分の補給を目的とした栄養補助食品として
製剤化し、効率よくコエンザイムQ10を摂取することができる。
(コエンザイムQ10含有組成物の調製方法)
本発明の、セサミン類とコエンザイムQ10とを含む組成物は、油に溶解して摂取する
ことが好ましい。使用できる油としては、セサミン類及びコエンザイムQ10を溶解でき
るものであれば、特に制限されないが、具体的には、常温で液状の油である、大豆油、菜
種油、サフラワー油、オリーブ油、綿実油、トウモロコシ油、パーム油、米糠油、小麦胚
芽油、ヒマワリ油、ベニバナ油、落花生油、鯨油、イワシ油、イカ油などの天然動植物油
、中鎖長脂肪酸トリグリセリド、炭素数4〜22の脂肪酸のモノ、ジ及びトリグリセリド
またはこれらの混合物等を例示できる。また、半固体状または固体状である、ラード、牛
脂、水素添加魚油、マーガリン、ショートニング等と、上記の常温で液状油とを混合した
ものを使用することもできる。
The form of the health food containing coenzyme Q10 and sesamin is not particularly limited. For example, it is a solid such as powder, granule or tablet; a solution such as liquid or emulsion; or a paste It can be prepared in any form such as a semi-solid form. For example, in the case of a food containing a composition containing coenzyme Q10 and sesamin and / or episesamin as an active ingredient, since all of these ingredients are fat-soluble, microcapsules By encapsulating in soft capsules or hard capsules, it can be formulated as a nutritional supplement or supplementary nutritional supplement for the purpose of supplementing nutritional components, and coenzyme Q10 can be efficiently ingested.
(Method for preparing coenzyme Q10-containing composition)
The composition containing sesamin and coenzyme Q10 of the present invention is preferably taken after being dissolved in oil. The oil that can be used is not particularly limited as long as it can dissolve sesamin and coenzyme Q10. Specifically, soybean oil, rapeseed oil, safflower oil, olive oil, cottonseed oil, which is a liquid oil at room temperature, Natural animal and vegetable oils such as corn oil, palm oil, rice bran oil, wheat germ oil, sunflower oil, safflower oil, peanut oil, whale oil, sardine oil, squid oil, medium chain length fatty acid triglyceride, monohydric fatty acid having 4 to 22 carbon atoms , Di- and triglycerides or a mixture thereof. Further, a mixture of lard, beef tallow, hydrogenated fish oil, margarine, shortening, etc., which is semi-solid or solid, and liquid oil at normal temperature as described above can also be used.
以下に、セサミン類と、コエンザイムQ10とを含有する本発明の組成物の製造方法に
ついて説明する。しかしながら、本発明の組成物は、これらの製造方法によって製造さっ
るものに限定されるものではなく、当業者が容易に想到するどのような製造方法で製造し
ても良い。
Below, the manufacturing method of the composition of this invention containing sesamin and coenzyme Q10 is demonstrated. However, the composition of the present invention is not limited to those produced by these production methods, and may be produced by any production method easily conceived by those skilled in the art.
まず、セサミン類を油脂に溶解させる。この際、油脂は加温しておくことが好ましく、
その温度は、通常、70〜150℃、好ましくは100〜120℃である。セサミン類を
溶解した後、この溶液中にコエンザイムQ10を添加する。コエンザイムQ10は、高温
中で不安定なため、油脂を70℃以上に加温した場合には、40〜60℃、好ましくは5
0℃程度に冷却した後に、コエンザイムQ10を添加するのがよい。なお、任意の段階で
、乳化剤であるミツロウ、グリセリン脂肪酸エステル,ビタミンE等を加え、必要に応じ
、懸濁状にするなどの工程を加えてもよい。
First, sesamins are dissolved in fats and oils. At this time, it is preferable to heat the fat and oil,
The temperature is usually 70 to 150 ° C, preferably 100 to 120 ° C. After dissolving the sesamins, coenzyme Q10 is added to this solution. Since Coenzyme Q10 is unstable at high temperatures, when oils and fats are heated to 70 ° C. or higher, 40 to 60 ° C., preferably 5
After cooling to about 0 ° C., coenzyme Q10 is preferably added. In addition, you may add the process of adding beeswax, glycerin fatty acid ester, vitamin E, etc. which are emulsifiers in an arbitrary stage, and making it a suspension form as needed.
また、コエンザイムQ10は光劣化を起こし易いため、例えば、着色色素としてカラメ
ル色素を混入させたカプセル材料を使用して作成したカプセルに、コエンザイムQ10を
含む組成物を封入し、内容液が光に晒されないようにして、コエンザイムQ10の変質を
防ぐことが好ましい。
In addition, since coenzyme Q10 is susceptible to photodegradation, for example, a composition containing coenzyme Q10 is encapsulated in a capsule prepared using a capsule material mixed with caramel dye as a coloring dye, and the content liquid is exposed to light. It is preferable to prevent alteration of coenzyme Q10.
以下、実施例に基づいて本発明の説明をするが、これらの実施例は本発明を限定するた
めのものではない。なお、実施例で使用したコエンザイムQ10は、日清ファルマ株式会
社製のコエンザイムQ10であった。
[実施例1]ラットにおけるコエンザイムQ10吸収力の評価(1)
セサミン類としては、セサミン(竹本油脂製、セサミン:エピセサミン=56:44)
を用いた。SD系雄性ラット(8週齢)を、対照(オリーブ油)群と、コエンザイムQ1
0群と、コエンザイムQ10+セサミン群(各群4匹)とに分けた。下記の表1に示すよ
うに、それぞれの成分をオリーブ油に溶解することで組成物を調製し、単回投与の後、0
、2、4、6及び7時間後に血液を採取して血漿中コエンザイムQ10濃度の経時変化を
測定した。
EXAMPLES Hereinafter, although this invention is demonstrated based on an Example, these Examples are not for limiting this invention. The coenzyme Q10 used in the examples was coenzyme Q10 manufactured by Nisshin Pharma Co., Ltd.
[Example 1] Evaluation of absorbability of coenzyme Q10 in rats (1)
As sesamin, sesamin (made by Takemoto Yushi, sesamin: episesamin = 56: 44)
Was used. SD male rats (8 weeks old) were compared with a control (olive oil) group and coenzyme Q1.
Divided into
Blood was collected after 2, 4, 6 and 7 hours, and the time course of plasma coenzyme Q10 concentration was measured.
[実施例2]ラットにおけるコエンザイムQ10吸収力の評価(2)
コエンザイムQ10とセサミンとを含有する組成物を、下記の表2に示す配合となるよ
うに調製する以外は、実施例1と同様に処理して、血漿中コエンザイムQ10濃度の経時
変化を測定した。採血時間は0,2,4,6,8,10,24時間目とした。なお、比較
例として、セサミンに代えて、抗酸化剤として知られているビタミンEを配合した組成物
についても同様の実験を行った。
[Example 2] Evaluation of coenzyme Q10 absorbency in rats (2)
A time course change of plasma coenzyme Q10 concentration was measured in the same manner as in Example 1 except that a composition containing coenzyme Q10 and sesamin was prepared to have the formulation shown in Table 2 below. The blood collection times were 0, 2, 4, 6, 8, 10, 24 hours. As a comparative example, a similar experiment was conducted for a composition containing vitamin E, which is known as an antioxidant, instead of sesamin.
[実施例3]ラットにおけるコエンザイムQ10吸収力の評価(3)
コエンザイムQ10含有組成物、及びコエンザイムQ10とセサミンとを含有する組成
物を下記の表3の配合となるように調製する以外は、実施例2と同様にして血漿中コエン
ザイムQ10濃度の経時変化を測定した。
[Example 3] Evaluation of absorbability of coenzyme Q10 in rats (3)
Coenzyme Q10-containing composition and coenzyme Q10 and sesamin-containing composition were prepared in the same manner as in Example 2 except that the composition shown in Table 3 was prepared. did.
[実施例4]ラットにおけるコエンザイムQ10吸収力の評価(4)
実施例1〜3の結果より、コエンザイムQ10を単回経口投与した場合のTmax(最高血
中濃度を示す時間)は6時間であり、とくにセサミンは6時間目の血中濃度を上昇させる
ことから、6時間目の血中濃度を指標にコエンザイムQ10の血中濃度に及ぼすセサミン
の影響を評価した。コエンザイムQ10とセサミンとを含有する組成物を下記の表4の配
合となるように調製し、単回経口投与6時間目の血中コエンザイムQ10濃度を測定した
。
[Example 4] Evaluation of absorbability of coenzyme Q10 in rats (4)
From the results of Examples 1 to 3, Tmax (time for showing the maximum blood concentration) when coenzyme Q10 was orally administered once was 6 hours, and in particular, sesamin increased the blood concentration at 6 hours. The effect of sesamin on the blood concentration of coenzyme Q10 was evaluated using the blood concentration at 6 hours as an index. A composition containing coenzyme Q10 and sesamin was prepared to have the composition shown in Table 4 below, and the blood coenzyme Q10 concentration at 6 hours after single oral administration was measured.
実施例1〜4の結果を、図1〜図4に示す。図より明らかなように、実施例1〜3の条
件下では、コエンザイムQ10をオリーブ油に溶解した群と比較して、セサミンを併用し
たコエンザイムQ10+セサミン(オリーブ油に溶解)群では有意なコエンザイムQ10
量の増加が認められた。また、図2より、抗酸化剤として知られているビタミンEではコ
エンザイムQ10の体内吸収を向上させることができないことから、セサミンが特異的に
コエンザイムQ10の体内吸収を向上させることが示唆された。従って、本発明のコエン
ザイムQ10含有素材(組成物)を用いると、複雑な工程を経ることなく、極めて高いコ
エンザイムQ10の吸収性を実現できることが明らかとなった。
The results of Examples 1 to 4 are shown in FIGS. As is apparent from the figure, under the conditions of Examples 1 to 3, compared to the group in which coenzyme Q10 was dissolved in olive oil, the coenzyme Q10 in combination with sesamin Q10 + sesamin (dissolved in olive oil) group showed significant coenzyme Q10.
An increase in quantity was observed. Further, from FIG. 2, vitamin E, which is known as an antioxidant, cannot improve the in vivo absorption of coenzyme Q10, suggesting that sesamin specifically improves the in vivo absorption of coenzyme Q10. Therefore, it has been clarified that when the coenzyme Q10-containing material (composition) of the present invention is used, extremely high coenzyme Q10 absorbability can be realized without going through a complicated process.
また、図1〜図4の結果から、セサミン配合によるコエンザイムQ10の血漿濃度(吸
収量)の上昇比率(本発明組成物の吸収量/コエンザイムQ10のみの吸収量)を求め、
この値を、本組成物におけるコエンザイムQ10とセサミンとの配合割合に対してプロッ
トした(図5)。図5より、セサミン類は、コエンザイムQ10の配合量に対し、1/1
0以上配合すると、コエンザイムQ10の体内吸収量を高めることができることが示唆さ
れた。
[実施例5]
下記の表5に示す配合で、コエンザイムQ10とセサミン類とを含有する組成物を調製
した。これら組成物を専門パネラー10名により、胡麻油の匂い、後味、飲みにくさを下
記の3段階ランク(A,B,C)で官能評価を行った。また、相対的にどのコエンザイム
Q10含有組成物が好ましいかについて官能評価を実施した。コエンザイムQ10の量は
30mg、セサミン含有量は10mgとなるよう調整した(ごま油中のセサミン含有量は
約0.5%)。
Also, from the results of FIGS. 1 to 4, the increase ratio of the plasma concentration (absorption amount) of coenzyme Q10 by the combination of sesamin (absorption amount of the composition of the present invention / absorption amount of coenzyme Q10 alone) was determined,
This value was plotted against the blending ratio of coenzyme Q10 and sesamin in this composition (FIG. 5). From FIG. 5, sesamin is 1/1 with respect to the compounding quantity of coenzyme Q10.
It was suggested that the amount of coenzyme Q10 absorbed in the body can be increased by adding 0 or more.
[Example 5]
A composition containing coenzyme Q10 and sesamin was prepared with the formulation shown in Table 5 below. These compositions were subjected to sensory evaluation by the following 10 ranks (A, B, C) for the odor of sesame oil, aftertaste and difficulty in drinking. Moreover, sensory evaluation was implemented about which coenzyme Q10 containing composition is relatively preferable. The amount of coenzyme Q10 was adjusted to 30 mg, and the sesamin content was adjusted to 10 mg (sesamin content in sesame oil was about 0.5%).
試験(官能評価)の結果は表6及び表7に示す。 The results of the test (sensory evaluation) are shown in Table 6 and Table 7.
* 1位:5点、2位:3点、3位:1点にて結果を換算
上記表6、表7の結果から明らかなように、ごま油特有の風味が官能的に好ましくない
と評価されており、本発明の実施には無味無臭であるごま油からの抽出物(精製されたも
の)を用いるのがよい。また、本発明の組成物を他の飲食品に配合する場合も、その飲食
品本来の味、香りを損なわないように、無味無臭であるほうが好都合である。
* 1st place: 5 points, 2nd place: 3 points, 3rd place: 1 point converted results As is clear from the results in Tables 6 and 7 above, the flavor unique to sesame oil was evaluated to be sensuously unfavorable. In the practice of the present invention, it is preferable to use an extract (purified) from sesame oil that is tasteless and odorless. Moreover, when mix | blending the composition of this invention with other food-drinks, it is more convenient that it is tasteless and odorless so that the original taste and fragrance of the food-drinks may not be impaired.
また、表7に示すように、ごま油を用いた場合、セサミン含有量が0.5%程度と低い
ため、ある一定のセサミンを摂取しようとすると、250mg/カプセルを8粒摂取しな
ければならないのに対し、ごま油抽出物(精製されたもの)の場合2粒となり、少量摂取
でよいという観点からもごま油抽出物(精製されたもの)を用いることが好ましい。
[実施例6]
下記の表8に示す処方で、配合例1、2及び3の中味液を次のとおりの方法で製造した
。原料をすべて混合・均一化させ、コエンザイムQ10含有素材を得た。次いで、ゼラチ
ン、グリセリン、カラメルを加え、膨潤させ、溶解したゼラチンシートを用いて、打ち抜
き法により、ソフトカプセルを製造した。
In addition, as shown in Table 7, when sesame oil is used, the sesamin content is as low as about 0.5%, so if you want to ingest a certain sesamin, you must ingest 8 capsules of 250 mg / capsule. On the other hand, in the case of sesame oil extract (purified product), it is preferable to use the sesame oil extract (purified product) from the viewpoint that it becomes two grains and only a small amount may be consumed.
[Example 6]
With the formulation shown in Table 8 below, the liquid contents of Formulation Examples 1, 2, and 3 were produced by the following method. All the raw materials were mixed and homogenized to obtain a coenzyme Q10-containing material. Next, gelatin, glycerin and caramel were added, swollen, and soft capsules were produced by a punching method using the gelatin sheet dissolved.
[実施例7]
実施例6により調整したソフトカプセルを用い、ヒトにおける血中濃度を測定した。被験
者は健常な男女11名(男6、女5)を対象とし、A、B群の2つに分け、A群(n=5)をCoQ10+
セサミンEの摂取群、B群(n=6)をCoQ10のみの摂取群とした。試験サンプルの飲用期間は1
週間とし、その前後で採血を行い、血中CoQ10量を測定した。その結果、表9に示したよう
にA群の血中変化量がB群と比較して高いことが明らかとなった。
[Example 7]
Using the soft capsule prepared according to Example 6, the blood concentration in humans was measured. The subjects were 11 healthy men and women (6 men, 5 women), divided into two groups, A and B, and group A (n = 5) was CoQ10 +
The group ingested sesamin E and group B (n = 6) were ingested with only CoQ10. The drinking period of the test sample is 1
Blood was collected before and after the week, and the amount of CoQ10 in the blood was measured. As a result, as shown in Table 9, it was clarified that the amount of blood change in group A was higher than that in group B.
以上述べたように、本発明によれば、複雑な工程を経ずにセサミン類とコエンザイムQ
10を混合させることにより、コエンザイムQ10の体内吸収性が高まることで、コエン
ザイムQ10が持つ免疫賦活作用、老化予防作用等の生体機能増進を効率よく達成するこ
とができ、さらに、併せて、セサミン類による効能も達成できる。
As described above, according to the present invention, sesamin and coenzyme Q can be used without complicated processes.
By mixing 10 with the coenzyme Q10, the in vivo absorbability of the coenzyme Q10 can be increased, so that it is possible to efficiently achieve the biological function enhancement of the coenzyme Q10, such as the immunostimulatory action and the aging preventive action. The effect of can also be achieved.
Claims (8)
記載の組成物。 The composition according to claim 1, wherein the blending weight ratio of sesamin to coenzyme Q10 is 1/10 or more.
ずれかの項に記載の組成物。 The composition according to any one of claims 1 to 3, wherein the sesamin is a sesamin concentrate containing 1% or more of the sesamin.
載の組成物。 The composition according to any one of claims 1 to 5, wherein the sesamin is sesamin and / or episesamin.
内吸収性を高める方法。 A method for increasing the in vivo absorbability of coenzyme Q10, comprising combining sesamin with coenzyme Q10.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013105394A JP5735576B2 (en) | 2013-05-17 | 2013-05-17 | Composition containing coenzyme Q10 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013105394A JP5735576B2 (en) | 2013-05-17 | 2013-05-17 | Composition containing coenzyme Q10 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005261881A Division JP5683768B2 (en) | 2005-09-09 | 2005-09-09 | Composition containing coenzyme Q10 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013163690A true JP2013163690A (en) | 2013-08-22 |
JP5735576B2 JP5735576B2 (en) | 2015-06-17 |
Family
ID=49175275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013105394A Active JP5735576B2 (en) | 2013-05-17 | 2013-05-17 | Composition containing coenzyme Q10 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5735576B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105828623A (en) * | 2013-12-16 | 2016-08-03 | 三得利控股株式会社 | Composition Having High Sesamin Content |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5492616A (en) * | 1977-12-28 | 1979-07-23 | Ota Pharma | Ubidecalenone soft capsule preparation |
JPS5754117A (en) * | 1980-09-19 | 1982-03-31 | Eisai Co Ltd | Ubidecarenone-containing solid composition with high absorbability |
-
2013
- 2013-05-17 JP JP2013105394A patent/JP5735576B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5492616A (en) * | 1977-12-28 | 1979-07-23 | Ota Pharma | Ubidecalenone soft capsule preparation |
JPS5754117A (en) * | 1980-09-19 | 1982-03-31 | Eisai Co Ltd | Ubidecarenone-containing solid composition with high absorbability |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105828623A (en) * | 2013-12-16 | 2016-08-03 | 三得利控股株式会社 | Composition Having High Sesamin Content |
JPWO2015093484A1 (en) * | 2013-12-16 | 2017-03-16 | サントリーホールディングス株式会社 | Sesamin high content composition |
US10159740B2 (en) | 2013-12-16 | 2018-12-25 | Suntory Holdings Limited | Compositions with high content of sesamin class compounds |
Also Published As
Publication number | Publication date |
---|---|
JP5735576B2 (en) | 2015-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2202454T3 (en) | USE OF A BALANCING AGENT FOR OMEGA-3 AND OMEGA-6 Unsaturated FATTY ACIDS. | |
JP5546087B2 (en) | Oral treatment or prevention agent for skin diseases | |
JPS58189110A (en) | Nutritious lipid composition | |
JPWO2005061684A1 (en) | Oil composition | |
JP2005002035A (en) | Composition containing coenzyme q10 and fat combustion promoting agent | |
WO2008059965A1 (en) | Agent for alleviating or preventing stress symptoms and agent for improving mental conditions | |
JP6896417B2 (en) | Composition containing krill oil, fish oil and perilla oil | |
JP2006306813A (en) | Mast cell increase inhibitor | |
JP5735576B2 (en) | Composition containing coenzyme Q10 | |
JPS6115647A (en) | Oil and fat food | |
US20120184760A1 (en) | Removal of monoglycerides from fatty acid concentrates | |
JP5683768B2 (en) | Composition containing coenzyme Q10 | |
JP2005047851A (en) | Ubidecarenone-containing composition | |
TWI834743B (en) | Oral composition containing reduced coenzyme Q10, its manufacturing method, discoloration inhibitory method and discoloration inhibitor | |
KR20180075423A (en) | Composition comprising allulose for promoting discharge of vegetable lipids ex vivo | |
JP6203320B2 (en) | Oral treatment or prevention agent for skin diseases | |
JPH0469614B2 (en) | ||
JP2012082226A (en) | Oral agent for treatment or prevention of cutaneous disease | |
JP5258144B2 (en) | Method for producing solid coenzyme Q10 oral preparation with improved absorbability | |
JP6462790B2 (en) | Oral treatment or prevention agent for skin diseases | |
JP6018712B2 (en) | Absorption accelerator for unsaturated fatty acids | |
US20180110748A1 (en) | Composition for reducing or suppressing increase in neutral fat level containing n-3 unsaturated fatty acid, and use of n-3 unsaturated fatty acid in production of same composition | |
JP6214474B2 (en) | Oral treatment or prevention agent for skin diseases | |
JP2009179592A (en) | Qol improver | |
JPS6115649A (en) | Oily food |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130517 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140509 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140708 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141114 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150216 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150223 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150317 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150318 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150406 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150416 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5735576 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |